Buy, Sell or Hold? before and after EPS results Guardant Health (NASDAQ:GH)

0
126

Earnings results for Guardant Health (NASDAQ:GH)

Guardant Health, Inc. is expected* to report earnings on 11/05/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.34. The reported EPS for the same quarter last year was $-0.14.

Guardant Health last announced its quarterly earnings data on August 6th, 2020. The reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.17. The business earned $66.30 million during the quarter, compared to analyst estimates of $59.18 million. Its revenue for the quarter was up 22.8% on a year-over-year basis. Guardant Health has generated ($0.84) earnings per share over the last year. Guardant Health has confirmed that its next quarterly earnings report will be published on Thursday, November 5th, 2020.

Analyst Opinion on Guardant Health (NASDAQ:GH)

7 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. Their average twelve-month price target is $113.00, predicting that the stock has a possible downside of 0.35%. The high price target for GH is $130.00 and the low price target for GH is $100.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Guardant Health has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $113.00, Guardant Health has a forecasted downside of 0.4% from its current price of $113.40. Guardant Health has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Guardant Health (NASDAQ:GH)

Guardant Health does not currently pay a dividend. Guardant Health does not have a long track record of dividend growth.

Insiders buying/selling: Guardant Health (NASDAQ:GH)

In the past three months, Guardant Health insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $765,045,751.00 in company stock. Only 13.00% of the stock of Guardant Health is held by insiders. 84.23% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Guardant Health (NASDAQ:GH

Earnings for Guardant Health are expected to grow in the coming year, from ($1.50) to ($1.07) per share. The P/E ratio of Guardant Health is -89.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Guardant Health is -89.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Guardant Health has a P/B Ratio of 13.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here